Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with high unmet need, with a focus on cardiovascular and inflammatory conditions. Its lead commercial product is ARCALYST (rilonacept), an interleukin-1 blocker and the first FDA-approved therapy specifically for recurrent pericarditis. The company also holds approvals for rarer autoinflammatory indications and advances a broader immunology pipeline.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 137.8 | — | 8.5 | — |
| Q2 2025 | 156.8 | — | 17.8 | — |
| Q3 2025 | 180.8 | — | 18.4 | — |
| Q4 2025 | 202.1 | — | 14.2 | — |
| Q1 2026 | 214.3 | 55.5% | 22.6 | 164.6% |
| Q2 2026 | 243.6 | 55.4% | 25.4 | 42.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Oruka Therapeutics, Inc. (ORKA), Landstar System, Inc. (LSTR), Liquidia Corporation (LQDA), Churchill Downs Incorporated (CHDN), FirstService Corporation (FSV), Amneal Pharmaceuticals, Inc. (AMRX)